Overview

Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency

Status:
Completed
Trial end date:
2009-01-28
Target enrollment:
Participant gender:
Summary
This is a randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral modified-release hydrocortisone in comparison to conventional thrice-daily oral hydrocortisone tablets in patients with adrenal insufficiency
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Shire
Treatments:
Cortisol succinate
Epinephrine
Epinephryl borate
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Racepinephrine